Topical AK, non-melanoma cancer options show promise

Article

Newport Beach, Calif. — When it comes to potential topical treatments for actinic keratoses (AKs) and non-melanoma skin cancers, T4N5 liposome lotion (Dimericine, Applied Genetics Inc. Dermatics) leads the pack. The product is composed of the protein T4 endonuclease V in a liposome vehicle.

Related Videos
Related Content

The Retirement “Red Zone”: What You Need to Know to Score Financially

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Journal Digest: September 26

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

The Retirement “Red Zone”: What You Need to Know to Score Financially

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Journal Digest: September 26

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023

The Retirement “Red Zone”: What You Need to Know to Score Financially

September 27th 2023

The Cutaneous Connection: Exploring the Effects of Pollutants on Atopic Dermatitis

June 12th 2023

Journal Digest: September 26

September 26th 2023

The Cutaneous Connection: Managing Atopic Dermatitis With Emerging Techniques

March 9th 2023

Analyzing the Safety of JAK Inhibitors in Atopic Dermatitis Treatment

September 26th 2023

Abeona Submits Biologics License Application to FDA for EB-101

September 26th 2023
© 2023 MJH Life Sciences

All rights reserved.